Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The gut incretin hormones glucose‐dependent insulinotropic polypeptide ( GIP ) and glucagon‐like peptide‐1 ( GLP ‐1) are secreted after meal ingestion and work in concert to promote postprandial insulin secretion and regulate glucagon secretion. GLP ‐1 also slows gastric emptying and suppresses appetite, whereas GIP seems to affect lipid metabolism. The introduction of selective GLP ‐1 receptor ( GLP‐1R ) agonists for the treatment of type 2 diabetes and obesity has increased the scientific and clinical interest in incretins. Combining the body weight‐lowering and glucose‐lowering effects of GLP ‐1 with a more potent improvement of β cell function through additional GIP action could potentially offer a more effective treatment of diabetes and obesity, with fewer adverse effects than selective GLP‐1R agonists; therefore, new drugs designed to co‐activate both the GIP receptor ( GIPR ) and the GLP‐1R simultaneously are under development. In the present review, we address advances in the field of GIPR and GLP‐1R co‐agonism and review in vitro studies, animal studies and human trials involving co‐administration of the two incretins, as well as results from a recently developed GIPR / GLP‐1R co‐agonist, and highlight promising areas and challenges within the field of incretin dual agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“The GIPR and the GLP-1R are widely expressed; the GIPR has been observed in the pancreas, adipose tissue, gut, heart, pituitary gland, adrenal cortex and the brain [10], and the GLP-1R has been observed in the pancreas, heart, lungs, kidneys, stomach and enteric neurons as well as in the central nervous system [11].”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“glucose administered to match the plasma glucose levels attained during an oral glucose load [12,13].”
BackgroundUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 10×
“Although the co-administration treatment resulted in reduced blood glucose, it did not potentiate the effect of either mono-receptor agonist alone at the doses tested; however, co-administration did result in reduction of food intake, greater weight loss and decreased fat mass compared with each agonist alone and a pl…”
BackgroundMethodResultInfluentialA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 1×
“In contrast to the potent insulinotropic effect of GIP in healthy subjects, even high doses of GIP cannot acutely increase glucose-stimulated insulin secretion in patients with type 2 diabetes to anything near what is seen in healthy subjects [36].”
Background
Cited by
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
Central administration of GLP-1 and GIP decreases feeding in mice
NamKoong, C., Kim, M. S., Jang, B.-T., Lee, Y. H., Cho, Y.-M., & Choi, H. J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.031 · Cited by 114
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Hasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29
Legend of Weight Loss: A Crosstalk Between the Bariatric Surgery and the Brain
Lin, Z., & Qu, S. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04474-8 · Cited by 28
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
Metadata
- Authors
- Skow, M. A., Bergmann, N. C., & Knop, F. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-06-07
- Volume
- 18
- Issue
- 9
- Pages
- 847-854
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2384715846
- Cited by
- 56
- References
- 29
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.